LifeX Company Spotlight: Advanced Respiratory Technologies (ART)

In respiratory care, some of the most meaningful breakthroughs do not simply improve existing treatments - they redefine where life-sustaining care can be delivered.Advanced Respiratory Technologies (ART) , a pioneering spinout of Carnegie Mellon University, is developing a compact ambulatory artificial lung platform designed to help patients avoid invasive mechanical ventilation.

The ART system will provide respiratory support beyond the ICU by enabling patients to remain awake and mobile, while reducing the complexity, common staffing burden, and costs associated with conventional care. Rather than confining advanced respiratory support to an ICU bed with intense monitoring, ART is developing a therapy designed to get the patient moving and recovering.

➤Based In:
Pittsburgh, PA

➤Industry Vertical:
Medical Device

Unlike traditional mechanical ventilation, which often requires intubation and sedation, ART's approach is designed to support respiratory function while avoiding many of the complications associated with invasive ventilation. Mechanical ventilation and ECMO can be lifesaving interventions, but they are also associated with prolonged ICU stays, patient deterioration, increased resource utilization, and significant patient burden.

ART is engineering their platform to address these barriers by using an advanced oxygenation system to efficiently exchange oxygen and carbon dioxide while reducing blood-related complications common to existing devices.

ART combining innovations in oxygenator design, hemocompatibility, and system architecture to create a more effective respiratory support solution.

As Advanced Respiratory Technologies commercialization priorities evolved, the company joined the LifeX Connect Program, a curated initiative that embeds experienced operators within high-potential healthcare startups to help bridge the gap between innovation and market adoption.

Through Connect, ART matched with David Gibel whose experience directly aligned with the company's stage and commercialization needs. David, an experienced healthcare executive and startup operator with deep expertise in commercialization, business development, and growth strategy.

David has built his career on both sides of medtech: leadership roles at Boston Scientific, Guidant and Philips, and operating positions at venture-backed startups through multiple exits. David brought a pragmatic, operator-led perspective that complemented ART's deep expertise in engineering, clinical science, and regulatory development.

❝ Working with David Gibel through the LifeX Connect program added a seasoned layer of support that helped align our team, sharpen our strategy, and accelerate execution through the accelerator, keeping us focused on what matters most to investors and how we translate our work into a clear, fundable path forward.❞

David joined Advanced Respiratory Technologies (ART) as a strategic advisor and fractional business leader.

His mandate was investor readiness: identifying the value creating milestones, articulating the value proposition, defining the market opportunity, and sharpening the investor pitch. He worked with the founders to validate physician feedback and dig deep into clinical workflows, grounding the commercial story in how the technology will actually be used at the bedside.

Throughout the Accelerator, ART leveraged LifeX as a platform for coordinated execution. Through access to experienced operators, industry experts, investors, and targeted commercialization resources, the company gained opportunities to pressure-test assumptions, refine priorities, and strengthen key aspects of its growth strategy.

The result was a meaningful shift in clary and alignment, ART emerged with a more focused view of its initial market entry strategy, a stronger connection between engineering milestones and clinical value, and a more structured approach to investor engagement.

❝ The LifeX Accelerator program not only allows us to identify areas where we
need to improve our company and our positioning for investment, but also actively facilitates the closing
of these gaps!❞

David Gibel continues to work with ART as a business leader and advisor, guiding the company's fundraising strategy, priorities, and organizational growth as it advances towards first human use and next financing round.

His deepening role within the company reflects a core premise of the LifeX Connect program that an experienced operator embedded with a highly experienced technical team can help transition a company from an innovative concept to real world commercialization.